Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02347774 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)
A Phase 3 study, sponsored by Sunovion Respiratory Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 641
- Enrollment target
NCT02347774 is a Phase 3 study that has completed, run by Sunovion Respiratory Development. The registered enrollment target is 641 participants.
The verdict
NCT02347774, a Phase 3 study, has completed, sponsored by Sunovion Respiratory Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 641 participants
- Enrollment target
Study Summary
This is a trial of 12 weeks of treatment with nebulized SUN-101 using an Investigational eFlow® Closed System (CS) nebulizer in subjects with chronic obstructive pulmonary disease (COPD) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD 2014) guidelines.
Interventions
- DRUG SUN-101 50 mcg BID eFlow (CS) nebulizer
- DRUG SUN-101 25 mcg BID eFlow (CS) nebulizer
- DRUG Placebo eFlow (CS) nebulizer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 641 participants |
| Start Date | 2015-02 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02347774
The ClinicalTrials.gov registry entry for NCT02347774 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 641 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sunovion Respiratory Development, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which SUN-101 50 mcg BID eFlow (CS) nebulizer is the first listed.
NCT02347774 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02347774 about?
NCT02347774 is a clinical study titled "Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)". This is a trial of 12 weeks of treatment with nebulized SUN-101 using an Investigational eFlow® Closed System (CS) nebulizer in subjects with chronic obstructive pulmonary disease (COPD) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD 2014) guidelines.
What is the current status of trial NCT02347774?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 641 participants. The study started on 2015-02. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02347774?
The interventions under investigation include: SUN-101 50 mcg BID eFlow (CS) nebulizer (DRUG), SUN-101 25 mcg BID eFlow (CS) nebulizer (DRUG), Placebo eFlow (CS) nebulizer (DRUG).
Who is sponsoring clinical trial NCT02347774?
This trial is sponsored by Sunovion Respiratory Development, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.